A $4 Tongue Swab Test Detects Tuberculosis Within 30 Minutes

Why It Matters

Rapid, affordable TB detection at the point of care can close the diagnostic gap for millions, accelerating treatment initiation and reducing transmission in resource‑limited settings.

Key Takeaways

• MiniDock MTB detects TB in 86% of phlegm samples
• Tongue‑swab sensitivity reaches 80%, meeting WHO accuracy goals
• Device costs under $400 and runs on a power bank
• Test delivers results in 12‑25 minutes without lab infrastructure
• Does not yet identify drug‑resistant TB strains

Pulse Analysis

Tuberculosis remains the deadliest infectious disease, with over 10 million new cases annually and a quarter of patients never diagnosed. Traditional smear microscopy, a 150‑year‑old method, struggles with patients who cannot produce sputum and misses more than 40% of cases. Molecular diagnostics have improved sensitivity but demand costly laboratory infrastructure, limiting their reach in low‑resource settings. The WHO’s recent endorsement of a point‑of‑care test signals a shift toward decentralised screening, aiming to bring accurate diagnostics to the clinics where most TB patients first present.

MiniDock MTB, developed by Pluslife Biotech, translates a decade of oral‑swab research into a handheld platform that operates on a power bank or wall outlet. A $4 cartridge processes a tongue swab or sputum sample, heating and spinning it to release bacterial DNA, then delivers a result in 12‑25 minutes. In field trials across seven high‑burden countries, the device achieved 86% sensitivity on sputum and 80% on tongue swabs, meeting WHO’s performance criteria and outperforming smear microscopy by 24 percentage points. At under $400 per unit, the system offers a cost‑effective alternative to expensive lab‑based PCR machines, requiring only minimal training for health workers.

The broader impact could be transformative for global health programmes. By enabling rapid, on‑site testing, MiniDock MTB can shorten the diagnostic cascade, allowing same‑day treatment decisions and reducing community transmission. However, its current inability to detect drug‑resistant TB and reduced sensitivity in low‑bacterial‑load cases highlight the need for complementary diagnostics and ongoing assay refinement. As Pluslife accelerates development of resistance‑detecting cartridges and explores blood‑based biomarkers, the platform may evolve into a comprehensive TB screening toolkit, aligning with WHO’s goal of universal access to rapid, accurate diagnostics.